Skip to main content
Call

A broader view of high-risk HPV

HPV DNA testing detects viral DNA—even when the virus is not actively producing cancer-causing proteins.

That insight can help support screening decisions, streamline triage, and expand screening access—giving practices more ways to support patients across the cervical cancer screening journey.

Support confidence in diagnoses

High sensitivity helps support confidence in negative results and guideline-aligned 3- or 5-year screening intervals.2-4

Streamline triage decisions

HPV DNA testing provides individual results for HPV 16 and HPV 18, plus pooled results for 12 other high-risk genotypes—without additional reflex testing.5 These results can help support timely, guideline-aligned decisions.

Expand screening access

Patient self-collection provides another option for HPV screening, either in the office or at a Quest Patient Service Center. Built-in assay controls help confirm the presence of human cellular material and monitor for possible contamination, helping support sample quality and technical performance.

Designed for the way 
practices screen

Quest offers age-based Smart Codes to help streamline age-based Pap, HPV, and select STI screening orders.
Designed for the way practices screen

Cervical cancer screening options for different workflows

Quest offers co-testing, reflex testing, and individual test codes to support different clinical workflows and patient needs.

Supporting resources

* The cobas® HPV Test is indicated for routine cervical cancer screening as per professional medical guidelines, including triage of ASC-US cytology, co-testing (or adjunctive screen) with cytology, and HPV primary screening of women to assess the risk for cervical precancer and cancer. Patients should be followed-up in accordance with professional medical guidelines, results from prior screening, medical history, and other risk factors. Refer to the package insert for detailed information.
References

  1. Huang S, Gentil LG, Schmidt C, et al. Clinical performance of HPV DNA and HPV RNA assays for the detection of high-grade cervical lesions. J Low Genit Tract Dis. 2026;30(1):25-30. doi:10.1097/LGT.0000000000000925
  2. Christine B, Bush M, Thurakal A, et al. New cervical cancer screening guidelines from the US Department of Health and Human Services: strengthening women’s preventive health. JAMA. 2026;335(8):661-662. doi:10.1001/jama.2025.26456
  3. Perkins RB, Wolf AMD, Church TR, et al. Self-collected vaginal specimens for human papillomavirus testing and guidance on screening exit: an update to the American Cancer Society cervical cancer screening guideline. CA Cancer J Clin. 2026;76(1):e70041. doi:10.3322/caac.70041
  4. American College of Obstetricians and Gynecologists’ Committee on Clinical Consensus–Gynecology. Screening for cervical cancer. Obstet Gynecol. 2026;148(1):e63-e67. doi:10.1097/AOG.0000000000006257
  5. cobas® HPV Test. Package insert. Roche. 2015. Accessed July 1, 2026. https://www.accessdata.fda.gov/cdrh_docs/pdf10/p100020s017c.pdf
  6. Qin J, Martinez G, Holt HK, et al. Preferences among US women for cervical cancer screening with self-collected specimens for human papillomavirus testing. Obstet Gynecol. 2026;147(3):306-312. doi:10.1097/AOG.0000000000006147

Ready to explore your HPV testing options?

Let’s talk about how HPV DNA testing can support screening insight, triage, and flexibility.

 

This form is intended for healthcare providers, but if you are interested in HPV DNA testing for yourself, click here.

 

Please remember that email, including this web form, is not a secure method of communication. Do not submit personal information, including user names and passwords, social security numbers, or personal health information through this form.

924

* indicates required

Other resources

Interested in a deep dive on HPV DNA assay design? Learn more from the experts in this webinar from Roche Diagnostics.

Learn more